Pharma Capital

OBJ Limited to reveal licensing details

The halt will remain in place until Monday 24th April 2017.
shutterstock_578045545_58f7fdd71ae46.jpg
The company is focused on drug delivery technology

OBJ Limited (ASX:OBJ) has been granted a trading halt by the ASX, pending details in relation to the licensing of a second technology.

The halt will remain in place until the opening of trade on Monday 24th April 2017, or earlier if an announcement is made to the market.

View full OBJ profile

OBJ Limited Timeline

View All

Related Articles

© biotech Capital 2017

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.